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Abstract
Sarcoidosis is an orphan inflammatory disorder that can virtually affect any organ or system in the body, although the lungs and 
lymph nodes are most frequently involved. Sarcoidosis is believed to derive from an interaction between environmental and 
genetic agents. Many studies emphasize a strong association between certain human leukocyte antigen (HLA) alleles and sarco-
idosis susceptibility. Several new insights have allowed the further evaluation of other candidate genes with a potential function 
in the immunopathogenesis of sarcoidosis. 
This review summarizes recent advances in the identification of novel molecular markers that may play a role in different stages 
of disease, such as the acute phase of inflammation, granuloma formation and fibrosis. Furthermore, this article elucidates the 
role of both TGF-b/Smad and (HIF)-1a-VEGF-ING-4 signaling pathways in the development of sarcoidosis. The potential epigenetic 
regulation of the processes occurring in sarcoidosis by miRNA is also discussed.
Key words: sarcoidosis, molecular markers, pathogenesis
Pneumonol Alergol Pol 2015; 83: 462–475
Introduction
Sarcoidosis is a chronic, multisystem, inflam-
matory disease of unknown etiology. Patients are 
commonly young or in middle adulthood (20–39 
years) and can be either male or female. Howe-
ver a second peak above 50 year of age has been 
documented in female patients [1]. 
The most common universal clinical signs of 
sarcoidosis include pathological intrapulmonary 
lesions, such as those of the lung/thoracic lymph 
nodes (> 90%) [2], and extrapulmonary lesions of 
the skin (20–30%) [3], liver (impaired liver func-
tion tests in up to 80%) and/or spleen (5–10%) [4], 
eyes (20–50%) [5], cardiovascular system (2–27%) 
[6], central nervous system 10–25% [7] have been 
recognized. It is of note, that extrapulmonary 
sarcoidosis is recognized on the clinical basis 
much less frequently. 
The current diagnosis of sarcoidosis is based 
on its clinical and radiological picture, with the 
presence of non-caseating granuloma in tissue 
biopsy. The diagnosis needs to be documented 
by endobronchial ultrasonography or esophageal 
ultrasonography transbronchial needle aspiration 
(EBUS/EUS-TBNA), bronchial mucosal biopsy, 
transbronchial peripheral lung biopsy (TBLB), 
mediastinoscopy, or extrathoracic biopsy (skin, 
peripheral lymph nodes, mucosa, other organs). 
Only in patients with typical clinico-radiological 
picture (bilateral hilar lymph nodes enlargement, 
Löfgren syndrome) biopsy is not obligatory. The 
typical bronchoalveolar lavage (BAL) results 
(increased percentage of lymphocytes with CD4/
CD8 > 3.5) substantially increase the probability 
of the diagnosis [1].
There is no reliable and validated “gold 
standard”, which could be useful for a proper 
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diagnosis of sarcoidosis. Several basic elements 
have been already determined to support the di-
agnosis of this granulomatous disease, the most 
important including (1) clinical parameters and 
radiological findings, (2) tissue biopsy specimen 
that exposes noncaseating granulomas, (3) the 
absence of established granuloma genic agents 
and (4) exclusion of similar diseases [1].
Both respiratory function tests and poste-
ro-anterior chest radiographs are commonly used 
to estimate the severity and course of pulmonary 
sarcoidosis. Pulmonary sarcoidosis is commonly 
staged according to the 0–IV staging system [1]. 
In the estimation of sarcoidosis activity, such 
biochemical and cellular parameters as serum 
angiotensin converting enzyme (SACE) [8], C-re-
active protein (CRP), calcium metabolism index 
(such as serum calcium and 24 h urinary calcium 
loss) [9] as well as biomarkers such as lysozyme, 
soluble IL-2 receptor (sIL-2R) [10], chitotriosidase 
(CHIT1) [11], Krebs von den lungen-6 (KL-6) [12], 
neopterin [10], human cartilage glycoprotein 39 
(YKL-40) [13], and 8-isoprostane (8-IP) [14] have 
been used. Although their prognostic value has 
been considered in many studies, their clinical 
value has never been validated by larger studies 
[10, 11, 14]. 
Interestingly, few studies on sarcoidosis 
epidemiology have been published worldwide. 
According to ACCESS (A Case Control Etiologic 
Study of Sarcoidosis) the morbidity is estimated 
at around 16.5/100 000 in men and 19/100 000 
in women but with significant differences in 
frequency among races [15]. Sarcoidosis is rec-
ognized as occurring most frequently in African 
Americans and Scandinavians, and much more 
rarely in Southern European populations, such 
as those in France and Spain [16]. Recent data 
from years 2001–2005 presented in European 
Lung White Book estimate the mean prevalence 
in Europe at 4.68/100 000/year [17].
Remarkably, the background of sarcoidosis is 
not fully understood, but many hypotheses based 
on microbacterial [18], viral [19], autoimmune 
[20] and genetic-environmental theories [21, 22]. 
Of these, the most widely accepted appear to be 
the genetic-environmental theory.
Sarcoidosis is known to be connected with 
many different environmental agents. Some 
studies suggest that exposure to common envi-
ronmental inorganic or organic agent/s can trigger 
its development [9]. 
The micobacterial theory of sarcoidosis, 
based on the tuberculosis pathogenesis involved 
in its development, is widely understood. No 
studies have so far confirmed the presence of via-
ble Mycobacteria in pathologically altered tissue 
specimens obtained from patients with clinically 
confirmed sarcoidosis [23]. However, studies ba-
sed on molecular biology confirmed the presence 
of mycobacterial products such as superantigens 
(Sags) and membrane fragments or bacterial 
DNA in patients with sarcoidosis [24]. Therefore 
M. tuberculosis complex (MTC), M. smegmatis, 
M. avium-intracellulare have been proposed as 
possible etiological links with sarcoidosis [25]. 
Despite, there are many studies focused on M. 
tuberculosis as an etiological factor in sarcoidosis, 
but many results are ambiguous. So far, in the 
literature there is a lack of direct evidence that M. 
tuberculosis is the causative agent of sarcoidosis, 
but it is known that Mycobacterium tuberculosis 
heat shock proteins (Mtb-hsp) may be involved 
in the immune response both in patients with 
sarcoidosis (SA) and tuberculosis (TB). Some 
important differences in these responses were 
shown, most importantly in Mtb-hsp-stimulated 
T-cell cultures IL-4 levels were lower and those 
of IL-10 were higher in SA vs. TB. CD8+gδ+IL-4+ 
T-cell were detected significantly less often in 
Mtb-hsp-stimulated cultures in SA, whereas 
CD4+gδ+TCR cells were more frequent in stimu-
lated cultures in TB. Similarly, a different profile 
of secreted cytokines (IL-4, IL-6, IL-10, TNFa, 
INF-g) in the three treatment groups were found, 
showing higher levels of TNFa, IL-6 in stimulated 
SA cells [26].
Propionibacteria are also worthy of atten-
tion as etiological factors of sarcoidosis. Studies 
conducted by Abe et al. confirmed the presence 
of P. acnes in 78% of biopsied lymph nodes of 
Japanese patients with sarcoidosis compared to 
21% of control tissue [27]. Similar results were 
also obtained by Eishi et al. based on studies using 
polymerase chain reaction (PCR) methods. They 
found much higher total numbers of genomes of 
P. acnes or P. granulosum than those of M. tuber-
culosis [28]. Moreover, high titers of antibodies 
against lymphotropic DNA viruses: Epstein-Barr 
virus (EBV) [29] human herpesvirus (HHV) [30] 
and rubella have been found in patients with 
diagnosed sarcoidosis [31].
Oswald-Richter et al. report that peripheral 
anergy and an exaggerated, pulmonary CD4+ Th1 
response is involved in sarcoidosis pathogenesis 
[32]. They demonstrate CD4+ anergic responses 
to polyclonal TCR (T-Cell Receptor) stimulation 
both peripherally and within the lungs of sar-
coid patients [32]. The discovery of T-regulatory 
(Treg) cells subset (CD4+CD25+FOXP3+ and 
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CD4+CD39+) and later Th17 cells has changed 
the traditional concept of Th1/Th2 bipolarized 
adaptive immune response. In general, Treg cells 
are responsible for maintaining immune homeo-
stasis and preventing autoimmunity, whereas 
Th17 cells are a source of proinflammatory IL-17 
cytokine, and play crucial role in host immu-
nity towards extracellular bacterial and fungal 
pathogens [33]. Both cell subsets were shown to 
be involved in the pathogenesis of sarcoidosis: 
Treg cells may play a crucial role in abating the 
inflammatory process, whereas Th17 cells, by 
promoting a proinflammatory milieu (IL-17, IL-6, 
TNFa, GM-CSF) may be responsible for sustained 
inflammatory reaction. Huang et al. have shown 
the increased Th17/Treg ratio in peripheral blood 
and BAL fluid in active sarcoidosis, which was 
normalized with treatment [34]. The same results 
were reported by Tondell et al. [35], who revealed 
that IFN-g+ Th17 cells may represent a patho-
genic subset of Th17 cells, which are stimulated 
to IFN-g production by Th1 cells. An increased 
activity of Treg cells in peripheral blood, which 
may be overwhelmed by Th17-related response in 
lungs and other involved organs may be respon-
sible for peripheral anergy [36, 37].
Autoimmune theory is based on the observa-
tion that macrophages can present antigens and 
release cytokines (IL-2, IL-4, IL-6, IL-10, IL-12, 
TNF-a, INF-g, TGF-b) [38] involved in polarization 
of CD4+ T-cells to Th1 in the blood of patients 
with sarcoidosis. In sarcoidosis patients, oligo-
clonal expansion of CD4+ causes secretion of Th1 
cytokines [39]. It is commonly recognized that 
immunopathological factors are very important in 
the development of sarcoidosis, but that genetic 
factors also contribute to this disease [40].
An interesting and universal hypothesis on 
the pathogenesis of sarcoidosis was proposed by 
Dubaniewicz [20]. The theory is based on the 
Matzinger consept, according to which the anti-
gen presenting cells (APCs) responding to endog-
enous cell products (so called “danger signals”) 
released from host cells under stress caused by 
different infectious and non-infectious agents, 
may induce the immune response [41]. These 
external agents referred to as pathogen-associated 
molecular patterns (PAMPs) induce the release of 
damage-associated molecular patterns (DAMPs) 
from injured cells. According to “Danger theory” 
Mycobacterial hsp may act as PAMPs, whereas 
human hsp may act as DAMPs, and linking to 
pattern recognition receptors (PRR) on APCs both 
may induce the immune response leading to ac-
cumulation of Th1 lymphocytes and formation of 
granuloma. It is of note, that there is significant 
homology between many bacterial and human 
HSPs, therefore autoimmunity may play a role.
Genetic factors in sarcoidosis
Many previous studies have confirmed that 
genetic factors have a role in determining the 
risk, as well as clinical course, of sarcoidosis 
[1]. The pivotal genetic predisposition to sarco-
idosis was confirmed by observation of familial 
clustering in monozygotic twins, which are more 
often predisposed to disease than dizygotic twins. 
However, this genetic effect is multiple, small or 
moderate [42].
This theory is also supported by diversity of 
frequencies in the incidence of sarcoidosis in dif-
ferent populations. African Americans are known 
to be more frequently affected by sarcoidosis than 
Caucasians [1].
The risk of sarcoidosis is generally accepted 
as being associated with both HLA class I and 
class II human leukocyte antigens. Some alleles, 
HLA-DRB1*11, HLA-DRB1*12, HLA-DRB1*14, 
HLA-DRB1*15 [43, 44], are known to be strongly 
associated with the risk of sarcoidosis, while oth-
ers may play a protective role: e.g. HLA-DRB1*01, 
HLA-DRB1*04 [45]. Additionally, HLA genes such 
as HLA-DRB1*03 can be related to acute onset 
disease (Löfgren’s syndrome) [46], whereas others 
such as HLA-DQB1*0201 and HLA-DQB1*0602 
are associated with the chronic course of disease 
[47]. 
It was documented that some other MHC 
loci may also increase the risk of sarcoidosis. 
Interestingly, Morais et al. suggest that in Cauca-
sians, BTNL2, genetically independently inherit-
ed factor of the HLA class II genes, may act as a 
T-cell co-stimulatory molecule [48] and their SNP 
variants displays in different populations, both 
negative and protective role in the development 
of sarcoidosis [48–50]. Dubaniewicz et al. report-
ed [51], that DQB1*02, DQA1*0501 in Löfgren 
syndrome, and DRB1*15 in stage II sarcoidosis 
were more frequently present in sarcoidosis than 
in tuberculosis, what could explain — according 
to the authors — different disease patterns in pa-
tients subjected to the same etiologic factor [52].
Non-HLA genes have been also explored in 
terms of disease susceptibility and prognosis. 
For instance, Typiak et al. [53] found increased 
frequency of F allele of FCGR3A gene encoding 
receptor for Fc fragment of immunoglobulin G 
FcgRIIIa (F allele connected with increased recep-
tor affinity) in stage I sarcoidosis, but increased 
Justyna Kiszałkiewicz et al., Selected molecular events in the pathogenesis of sarcoidosis
465www.pneumonologia.viamedica.pl
frequency of V allele (connected with decreased 
receptor affinity) in stage II disease. The authors 
conclude, that V158F polymorphism of FCGR3A 
gene may be responsible for the clearance efficien-
cy of immune complexes (like those containing 
Mtb-hsp epitope), what may be important in terms 
of disease duration and chronicity. These obser-
vations also support the concept of autoimmune 
pathogenesis of sarcoidosis.
The authors of the present paper found 
strong association between MMP-9 T-1702-A gene 
polymorphism, with higher frequency of T allele 
and TT homozygotic genotype and sarcoidosis 
morbidity, however no associations with clinical 
parameters and prognosis were found [54].
Although genetic factors are recognized as 
important etiological elements of the disease, 
their interactions with environmental or immu-
nological factors have not been fully explained. 
It has been generally accepted that sarcoidosis 
occurs in genetically predisposed patients with 
an altered immune response to unknown envi-
ronmental factors [55]. 
The most probable interaction model be-
tween important genetic and environmental fac-
tors that influence the incidence of sarcoidosis is 
shown in Figure 1.
Risk regions and susceptibility genes 
Progress in molecular technologies such as 
high density genotyping chips, SNP analysis, and 
genetic mapping have resulted in the discovery 
of several new susceptibility genes, risk loci or 
allele variants which may be relevant in the dia-
gnosis and treatment of sarcoidosis. The whole 
genome association assay (GWAS) technique 
has had a huge influence on current knowledge 
concerning the pathogenesis of many complex 
human diseases, including sarcoidosis [22, 44]. 
The technique has identified genes located on 
6 chromosome (locus 6p12.1) which are impor-
tant for risk and course of sarcoidosis: C6orf65 
(BEND6), BAG2, KIAA1586, ZNF415 and RAB23. 
RAB23 was confirmed as a particularly important 
vital diagnostic genetic marker which may be 
helpful in the diagnosis of sarcoidosis. Signi-
ficant differences in the relative expression of 
RAB23 between sarcoidosis patients and healthy 
controls have been observed [56]. 
Moreover, RAB23 was found to interfere with 
Sonic hedgehog (Shh)Treg signaling pathway 
molecules, contributing to the overactivation of 
CD4+ T-cells and stimulation of epithelial repair 
in patients with sarcoidosis [56]. Other impor-
tant new risk loci for sarcoidosis are 11q13.1 
(candidate risk genes: KCNK4, PRDX5, PCLB3, 
with CCDC88B being the most promising) [57] 
and 12q13.3, with the most important genomic 
region appearing to be rs1050045 in the 39-un-
translated region (39 UTR) of OS9 (Osteosarcoma 
amplified 9) [58]. 
During the effector phase of granuloma for-
mation in sarcoidosis, inflammatory cells are re-
cruited to the granuloma by specific chemokines 
(IP-10, CCR2, RANTES, MCP-1) [59]. It has been 
reported that polymorphisms in the CCR2 gene 
are important factors in determining the risk of 
disease in some populations. It was documented 
that SNP G/A in position 64 (rs1799864) of the 
CCR2 gene is protective against sarcoidosis in a 
Japanese population [60].
Recently, some attempts have been made 
to identify the relationship between VEGF gene 
polymorphisms and susceptibility to sarcoido-
sis. A case-control study of Japanese patients 
[61] did not confirm any correlation between 
polymorphism VEGF (C/G in position 627) and 
predisposition to sarcoidosis. Another study on 
the genetic variation of TGF-b isoforms empha-
sizes the linking of several SNP in TGF-b1: C/T 
in position 509 (rs 1800469), T/C in position 29 
(rs 1800470), G/C in position 74 (rs 1800471) 
[62] and in TGF-b2: A/G in position 59941 (rs 
1891467) [63]. 
An additional important candidate on sar-
coidosis susceptibility gene is CC10, encoded 
Clara cell 1-kD-protein, which may inhibit such 
inflammatory mediators as INF-g, TNF-a or (IL)-1b 
[10]. It has been proven that SNP A/G in position 
38 in CC10 gene (rs 3741240) may be related to 
progressive sarcoidosis [64].
Expression markers associated with 
clinical course 
It has been claimed that many diverse poten-
tial genes may be involved in different clinical 
Figure 1. The most likely model of the interactions between the most 
important factors influencing the global incidence of sarcoidosis
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stages of sarcoidosis: e.g. acute phase inflam-
mation (TNF-a, INF-g, IL-2) [65], granulomatous 
inflammation and granuloma formation (IL-1, 
IL-6, IL-8, IL-15, TNF-a, INF-g, GM-CSF, RANTES, 
IP-10) [39, 66] or fibrosis (IL-4, IL-5, IL-9, IL-10, 
IL-13, TGF-b) [66, 67]. These genes are identified 
as a considerable in various signaling pathways 
involved in lung cell physiology. 
Acute phase of inflammation
IL-1, IL-6, IL-11, TNF-a, and other chemo-
kines, G-CSF and GM-CSF play a pivotal role in 
the acute inflammation of sarcoidosis [67]. In this 
phase of the disease, some cytokine genes, such 
as IL-1, IL-2 [68], IL-6 [68, 69], and TNF-a [68, 
70], have demonstrated altered mRNA expression 
levels. Interestingly, the expression of TNF-a was 
decreased in acute phase of inflammation [71], 
whereas higher levels of IL-2, IFN-g and IL-12 
mRNA expression was noted in patients with ac-
tive sarcoidosis compared to individuals with the 
non-active form of the disease [69]. Additionally, 
in the non-active form of sarcoidosis, mRNA 
expression of IL-4, IL-5 and IL-10 was decreased 
[69]. Lower levels of IL-17A mRNA expression 
was found in the CD4+ T-cells of patients with 
Lofgren’s syndrome, compared with those of 
healthy patients [72]. 
Granuloma formation 
A prolonged state of inflammation in the 
presence of chronic antigenic stimulation leads 
to the formation of granulomas [1]. In sarcoidosis, 
the formation of granulomas requires an interplay 
between APCs, antigen and T-cells [73]. Ziegen-
hagen et al. observed the spontaneous release of 
greater amounts of TNF-a in patients with active 
sarcoidosis than those with the inactive form of 
disease [74]. Similarly, elevated levels of TNF-a 
gene expression was observed in the BAL fluid 
of sarcoidosis patients compared with control 
subjects [70]. 
So far, vascular endothelial growth factor 
(VEGF) has been considered an important cyto-
kine involved in the pathological processes of 
sarcoidosis [75, 76]. VEGF has been identified 
as a relative factor playing an important role 
in the recruitment and activation of monocytes 
towards granuloma formation [77]. Only one 
report has noted a change in the transcription 
pattern and protein production of the VEGF 
gene in patients diagnosed with sarcoidosis in 
comparison to control subjects. Koyama et al. 
report the presence of significantly lower VEGF 
levels in BALF specimens obtained from sar-
coidosis patients compared to healthy controls 
[78]. Such low VEGF levels may contribute to 
the reduction of angiogenesis and induction of 
apoptosis in lung cells during the development 
of sarcoidosis. In contrast, a study by Sekiya et 
al. [76] revealed a high increase of VEGF level in 
the serum of patients with extrapulmonary sar-
coidosis. In addition, Tolnay et al. [77] reported 
the overexpression of VEGF receptors in activated 
macrophages, in multinuclear giant cells and in 
epithelioid cells of sarcoid granulomas. In the 
light of these findings, it has been suggested that 
VEGF can be considered a prognostic indicator 
of the severity of a disorder [61]. 
Fibrosis
Local shifts in the Th1/Th2 regulatory net-
works tilting the balance of Th2 lymphocytes and 
increasing the amount of anti-inflammatory cyto-
kines such as IL-4, IL-9, IL-10, IL-13 and TGF-b 
can encourage progression to fibrosis [39]. As a 
result, fibrogenesis via expansion of the mesen-
chymal cell population with increased deposition 
of matrix compoments has been observed [79]. 
Increased levels of IL-10 [69], IL-13 [70] mRNA 
have also been observed in the BALF of patients 
with sarcoidosis who have recently developed 
growing systemic symptoms. 
As a multifunctional cytokine, TGF-b plays 
an important role in the initial steps of chronic 
inflammation and fibrogenesis. Moreover TGF-b is 
a key cytokine involved in inflammatory process-
es: while it acts as a pro-inflammatory cytokine, 
stimulating the T cells and macrophages, in the 
early stages of inflammation, it demonstrates 
anti-inflammatory and immunosuppressive prop-
erties and stimulates the process of fibrosis in the 
later stages [80]. Increased immunoexpression of 
TGF-b has been found in alveolar macrophages, 
lung epithelial cells and myofibroblasts. Among 
the mammalian TGF-b isoforms (TGF-b1–b3), 
TGF-b1 leads to increased deposition of extracel-
lular matrix (ECM) and is most strongly involved 
in the pathology of fibrosis involved in sarcoid-
osis [81]. TGF-b2 has been suggested to have a 
wound healing effect in lung inflammation [82]. 
Although the role of the third isoform (TGF-b3) 
is not fully understood, it is possible that it acts 
as an anti-fibrotic factor [83]. 
Higher serum levels of TGF-b1 in patients 
with pulmonary sarcoidosis may be associated 
with the progression of the disease, as well as 
with an increased risk of lung fibrosis [84]. 
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Signaling pathways important in 
sarcoidosis
TGF-b/Smad signaling pathway 
The TGF-b/Smad signaling pathway is in-
volved in many key cellular processes in both the 
adult organism and developing embryo, including 
those concerned with cell growth, differentiation, 
apoptosis and cellular homeostasis. In lung tissue, 
the TGF-b/Smad signaling pathway participates 
especially in airway remodeling, peribronchial 
fibrosis and wound healing [85]. This pathway is 
a distinctive signal transduction pathway which 
can transmit signals directly from cell surface 
receptors by interacting with DNA binding mol-
ecules and with transcriptional coactivators and 
corepressors. Abnormalities in TGF-b expression 
are very common in fibrotic diseases, including 
sarcoidosis, characterized by excessive produc-
tion, admission, and reduction of extracellular 
matrix (ECM) [84, 86]. 
As a result of TGF-b receptors (TbRI and 
TbRII) activation via phosphorylation following 
binding to the TGF-b ligand, Smad 2/3 proteins 
complex, the pathway may be sequentially ac-
tivated. During Smad 2 and 3 activation, Smad 
complex formation with Smad 4 is initiated. The 
Smad2/Smad3/Smad4 complex migrates to the 
cellular nucleus and interacts with the SBE (Smad 
binding element) as well as transcription factor 
binding element (TFBE). The interaction between 
Smad proteins complex and transcription factors 
may control the expression of certain genes, in-
cluding genes encoding the extracellular matrix 
(see Figure 2).
Interestingly, TGF-b also induces Smad 7 
through a Smad 3- and Smad 4-dependent mech-
anism. It was suggested that TGF-b can suppress 
Smad 3/4 action via the overexpression of Smad 7 
[87]. Smad 7 can act as an inhibitor by suppress-
ing the phosphorylation of Smad 2 and Smad 3 
via ubiquitination by Smurf2 ubiquitin-protein 
ligase. This process contributes to the degrada-
tion of the TGF-b R1 and R2 receptor complex, 
inhibiting TGF-b signaling as a consequence [88]. 
It is also suggested that Smad 7 gene expression 
influences lung airway remodeling and lung in-
juries, leading to fibrosis through regulating the 
magnitude of TGF-b signaling [89].
There is considerable evidence that Smad 
2 and Smad 3 play different biological roles in 
-b/Smad signaling in both epithelial cells and 
fibroblasts [90]. Particularly in fibroblasts, Smad 
3 is known to be required for gene expression 
induced by TGF-b, as it has been documented in 
Figure 2. TGF-b/Smad signaling pathway in the remodeling of ECM 
in fibrosing diseases, including sarcoidosis. Abbreviations: TGF-b — 
transforming growth factor-b, TGF-bI — transforming growth factor-b 
receptor 1, TGF-bII — transforming growth factor-b receptor 1, Smad 
2 — mothers against decapentaplegic homolog 2 protein, Smad 3 — 
mothers against decapentaplegic homolog 3 protein, Smad 4 — moth-
ers against decapentaplegic homolog 4 protein, Smad 7 — mothers 
against decapentaplegic homolog 7 protein, SBE — Smad binding 
element, TFBE — transcription factor binding element
gene expression profiles of adult Smad3_/_ mice 
models [91]. 
It has been also documented that TGF-b/
Smad2/3 plays a crucial role in inflammation 
processes. It acts as inhibitor of such inflamma-
tory cytokines as IL-2, IL-4 and INF-g in T-cells 
by binding many important regulatory proteins 
to Smads, such as the antiproliferative factor 
Tob [92] or the T-bet [93] molecule: a critical 
transcription factor for INF-g production and Th1 
differentiation of CD4+ T-cells. 
There is evidence that the TGF-b/Smad sig-
naling pathway plays a crucial role in the progres-
sion from acute inflammation to chronic fibrosis. 
Bonniaud et al. suggested that the process of 
inflammation may be sufficient to induce fibro-
sis when it proceeds through the TGF-b/Smad 3 
pathway [94]. Recently up-regulation of TGF-b1 
and SMAD3 genes in sarcoidosis patients present-
ing signs known to be related to worse prognosis 
(insidious disease onset, parenchymal involve-
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ment, lung function impairment) confirmed that 
elements of this pathway may be critical for the 
development of unfavorable outcome in sarcoid-
osis [95].
Current findings show that the activity of 
sarcoidosis can be marked by the process of ECM 
remodeling, related to the balance between im-
mune cells and tissue remodeling [96]. It is com-
monly suggested that ECM is a Smad 3-dependent 
process [97]. Several studies have documented 
that TGF-b promotes fibrosis both by synthesis 
and the inhibition of ECM degradation through 
downregulating expression of matrix-degrading 
enzymes and increasing expression of MMP in-
hibitors, mainly via Smad 3 [98]. These processes 
are shown in Figure 2.
To summarize, the TGF-b/Smad signaling 
pathway may be an important molecular mech-
anism in the controlling contortion of inflam-
matory processes and fibrogenesis during the 
development of pulmonary sarcoidosis. 
(HIF)-1A–VEGF-ING-4 axis
Although the exact mechanism of VEGF over- 
or under-expression in sarcoidosis has not yet 
been well established, a basic explanation of its 
transcriptional regulation has been proposed [99]. 
HIF-1a is a subunit of hypoxia-inducible 
factor 1 (HIF-1), which is a heterodimer based 
on a helix-loop-helix structure. The function 
and stability of HIF-1A might be immediately 
regulated by oxygen availability [100]. Under 
normoxic conditions, HIF-1A undergoes degra-
dation via the ubiquitin-proteasome pathway. 
It has been proven that the von Hippel-Lindau 
tumor suppressor gene product (pVHL) plays a 
pivotal role in this process [101]. In turn, de-
creased O2 levels result in HIF-1a accumulation 
within the cell due to the impaired action of 
pVHL [101]. HIF-1A is recognized as the most 
critical regulator of VEGF transcription [100]. 
Moreover, VEGF was identified as a pleiotropic 
factor in sarcoidosis. It has been documented as 
an important regulator of monocyte recruitment 
towards granuloma formation. The expression of 
VEGF within sarcoid granuloma was found to be 
raised [77]. These observations support the con-
cept of “immunoangiostasis” explaining sarcoid 
granuloma formation [77].
HIF-1A expression is modulated not only by 
changes in cellular oxygen concentration, but 
also by the activity of distinct factors including 
insulin growth factor (IGF), tumor necrosis factor 
(TNF-a), as well as inhibitor of growth 4 (ING-4) 
expression. [99]. 
ING-4 is a nuclear factor: a tumor suppressor 
gene that interacts with nuclear factor-kappa B 
(NF-kB) and represses its transcriptional activity. 
ING-4 is known to belong to a family of proteins 
containing a highly conserved C-terminal plant 
homeodomain (PHD)-like zinc-finger domain 
[102]. The action of ING-4 is strongly implicated 
in several important cellular processes includ-
ing angiogenesis, apoptosis, cell cycle control, 
proliferation and DNA repair [99, 102]. Under 
hypoxic conditions, ING-4 directly interacts 
with HIF prolyl-hydroxylase 2 (HPH-2) leading 
to HIF-1A downregulation, which may represent 
a possible mechanism for the promotion of an-
giogenesis [102]. Tzouvelekis [99] reported an 
impairment of the HIF-1A–VEGF axis resulting 
in ING-4 overexpression. The combination of 
the downregulation of HIF-1A within sarcoid 
granulomas with VEGF and ING-4 up-regulation 
may be the cause of the angiostatic environment 
found within granulomas, as well as the macro-
phage chemotaxis within sarcoid lesions [99]. 
In contrary, up-regulation on transcriptional 
level of proangiogenic factors such as HIF-1A and 
VEGF genes in PB lymphocytes of sarcoidosis 
patients has been documented [103]. Moreover 
the negative correlation between expression level 
of mRNA HIF-1A and lung function test results 
(FEV1/FVC) in sarcoidosis patients with paren-
chymal involvement has been documented [103]. 
This is an important observation due to the fact 
that observed up-regulation of HIF-1A may inhibit 
the epithelial cell repair and therefore may render 
the epithelial lung injury towards pulmonary 
fibrosis in sarcoidosis patients. 
Wnt/b-catenin signaling pathway
It has been documented that this signaling 
pathway is necessary for lung branching and 
distal airway cell specification [104, 105]. The 
Wnt/b-catenin regulate many biological processes 
in epithelial cells such as: fate determination, 
motility and polarity. Recent reports show that de-
regulated Wnt/b-catenin signaling has disastrous 
consequences in embryonic development [106]. 
It is recognized that Wnt/b-catenin signaling may 
play an important role in the lung inflammation 
and fibrotic processes and responses. Several of 
the target genes of the Wnt/b-catenin pathway 
such as: COX-2 (cyclooxygenase-2) [107], MMPs 
(matrix metalloproteinases) [108], VEGF [109] 
as well as c-myc [110] have been shown to be 
increased in sarcoidosis patients. In aspect of sar-
coidosis pathogenesis, there are many published 
evidences confirming Wnt/b-catenin signaling 
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involvement in the epithelial-mesenchymal 
transition (EMT), an pivotal process maintain 
mainly the fibrosis occurring in the progression 
of sarcoidosis [111]. 
Programmed death-1 pathway
PD-1 was mentioned for the first time in 1992 
by Ishida and co-workers [112]. PD-1 is expressed 
in various types of cells such as T-cells, Tregs, 
exhausted T-cells, B-cells, activated monocytes, 
DCs, and natural killer (NK) cells [113]. It is 
known that inhibitory receptors, such as program-
med death-1 (PD-1), negatively impact CD4+ T-
cell function [114]. PD-1 signaling is mediated by 
two different phosphatases: src homology region 
2 domain-containing phosphatase (SHP)-1 and -2. 
When PD-1 is activated, these phosphatases block 
the PI3K/Akt (phosphatidylinositol 3 kinase/Akt) 
signaling pathway, leading to reduced T-cell acti-
vation. Ligation of PD-L1 or PD-L2 on an antigen
-presenting cell with PD-1 on the T-cell results in 
the inhibition of PI3K-AKT, leading to a decrease 
of cytokine production, especially IL-2, and in-
hibition of LAT-Zap70 leading to a reduction of 
T-cell proliferation, and ultimately, inhibition of 
C3G-Rap1signaling, which causes a reduction of 
T-cell adhesion [115, 116]. In some granuloma-
tous diseases such as chronic beryllium disease 
(CBD), inhibition of the PD-1 signaling pathway 
restores T-cell function [117]. Braun et al. repor-
ted increased numbers of PD-1+ CD4+ T-cells in 
patients with sarcoidosis, especially in the BAL 
fluid, connected with spontaneous expression of 
such cytokines as IL-2 and IFN-g, compared with 
systemic T-cells. According to the authors, PD-1 
expression carries immunologic consequences in 
sarcoidosis pathogenesis [118]. 
miRNA — a new promising epigenetic regulator 
of sarcoidosis?
MicroRNAs (miRNAs) are identified as small, 
endogenous non-coding RNAs (20–25 nucleotides) 
able to negatively regulate gene expression at the 
post-transcriptional level [119, 120]. Even though 
up to hundreds of human microRNAs are known, 
knowledge of their pathological role in human 
diseases including sarcoidosis is still limited. 
Recent studies suggest that miRNAs play 
a significant role in immune responses via the 
indirect control of their own production, as well 
as their influence on the actions of other miRNAs 
[121]. However the role of particular miRNAs in 
inflammatory and fibrosis processes accompa-
nying sarcoidosis remains unexplored [122]. 
A recently conducted study confirmed that 
miRNAs are included in the process of altering 
the immune response to bacterial components 
such as lipopolysacharide (LPS), which stimulate 
toll-like receptors (TLRs) [123]. Recent studies 
have shown that miRNAs are involved in the 
regulation of immune cells, including the de-
velopment and differentiation of B- and T-cells 
(e.g. miR-155 [124], miR-181a [125] and cluster 
miR-17~92 [126]), as well as in the regulation 
of immune response (miR-155) [127], and the 
maintenance of the overall balance of the pro- 
and anti-inflammatory signals determining the 
progress or chronic state of inflammation (miR
-146a) [128]. Moreover, many classes of miRNAs 
are recognized as pivotal in lung development, 
cell lung homeostasis (miR-155, miR-26a, miR-29, 
let-7f, miR-223, miR-146a) and act as regulatory 
factors in several pulmonary diseases (miR-155, 
miR-126) [129]. The interaction of miRNAs and 
cytokines contributes to the immune response 
mediated by T and B lymphocytes. 
The most important miRNAs involved in 
pathological processes in the lung include miR-
126, miR-7, miR-21, miR-29, miR-30, miR-17-92, 
let-7d, miR-155, miR-223. It has been documented 
that miR-126 is downregulated in cystic fibrosis 
airway epithelial cells [130]. Moreover, miR-
155 and miR-21 have been recognized as being 
involved in allergic lung inflammation, with 
decreased expression being documented therein 
(see Figure 3) [129, 131].
Due to the fact that non-caseating granu-
lomatous changes may be found in the lung in 
90% of diagnosed sarcoidosis cases, many stu-
dies focus on miRNAs which are involved in the 
pathological processes occurring in the lungs. 
These studies mainly concern uncontrolled lung 
inflammation [128], pulmonary fibrosis and cystic 
fibrosis (see Figure 3) [132]. 
It should be stressed that expression of miR-
NAs in the lung is very specific, highly conserved 
and dependent on physiological and pathological 
conditions. However, knowledge concerning this 
issue is still limited and typically based on animal 
models [133].
Pulmonary fibrosis is associated with extra-
cellular matrix (ECM) remodeling and also regu-
lated by miRNA. Degradation of ECM components 
leading to fibrosis is associated with excessive 
accumulation of collagens, fibronectins and ela-
stin [134]. 
In the development of pulmonary fibrosis 
(both in IPF and in the course of sarcoidosis), 
some classes of miRNA can be downregulated 
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(let-7, miR-29, miR-30, miR-17-92 while others 
can be upregulated (miR-21, miR-155). Remarka-
bly, miR-155 is involved in the regulation of many 
inflammatory processes. Its expression can be re-
gulated by transcription factors NF-kb or AP-1 and 
cytokines such as TNF-a and IL-1b. Upregulated 
expression of this miRNA leads to the reduction 
of keratinocyte growth factor (KGF) in normal 
pulmonary fibroblasts, leading to increased fibro-
blast migration via activation of caspase 3 [134]. 
Upregulated expression of miR-21 in pulmonary 
fibrosis is associated with miRNA-21 regulation 
of the TGF-b signaling pathway. Both factors, miR-
21 and TGF-b, work in a feed-forward loop. TGF-b 
induces miR-21 expression and miR-21 in turn 
promotes TGF-b-induced fibrogenic activation of 
pulmonary fibroblasts via the inhibition of Smad 
7 and the reduction of Smad 2 [136, 137]. 
A study conducted by Xiao et al. found that 
miR-29 is the downstream target gene of Smad 3 
and is negatively regulated by the TGF-b/Smad 
signaling pathway [138]. Moreover, miR-29 is also 
involved in EMT [139]. 
The miR-17~92 cluster is known to encode 
six miRNAs (miR-17, miR-18a, miR-19a, miR-20a, 
miR-19b-1, and miR-92-1) [126, 140], which are 
decreased in patients with IPF. These six miR-
NAs are also important in the development of 
lung epithelial cells with high expression during 
the embryonic phase which then declines into 
adulthood [126]. This is surprising, as so far no 
studies on sarcoidosis have been published con-
cerning the modulation of this miRNA cluster. 
Our current finished studies (data not published) 
focus on many selected classes of miRNAs has 
documented that some classes of miRNAs (e.g. 
miR-192 and miR-221) are upregulated in sarco-
idosis patients. Moreover, miR-16 and miR-20a 
were significantly increased in patients with lung 
volume restriction while miR-let7f increased in 
patients with bronchial obstruction. Our results 
suggest regulatory role of miRNAs in sarcoidosis 
and indicate that some of them may have a nega-
tive prognostic value.
Which miRNAs targeting signaling 
pathway may be important in sarcoidosis?
Smad 7, the signaling protein in the TGF-b/
Smad signaling pathway thought to be important 
in fibrosis, is known to be a direct target of miR-
21. Overexpression of this microRNA in primary 
pulmonary fibroblasts inhibits Smad 7 and as a 
consequence, regulates the TGF-b/Smad pathway. 
A molecule miR-21 is known to belong to a group 
of miRNAs (miR-21, miR-32, miR-136, miR-137, 
miR-192, miR-210, miR-211, miR-346) that par-
ticipates in the regulation of TGF-b-dependent 
endothelial-mesenchymal transition (EMT) [141, 
142]. During the process of fibrogenesis, various 
microRNAs such as miR-196b, miR-704, miR-717, 
miR-16, miR-195, miR-10a, miR-211, miR-34a, 
miR-367, miR-21 and let-7 are activated and target 
the TGF-b, Smad 3,6,7 and TGF-bRs I and II genes 
from the TGF-b/Smad signaling pathway [143].
Figure 3. The deregulated classes of miRNA involved in the pathological processes occurring in the lungs. Abbreviations: miR — microRNA, 
↓decreased expression, ↑ increased expression
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Figure 4. Important DE-miRNAs identified in lung sarcoidosis tissue, focusing on particular molecules participating in the TGF-b/Smad signaling 
pathway [110, modified]. Abbreviations: TGF-b — transforming growth factor-b, TGF-bI — transforming growth factor-b receptor 1, TGF-bII — 
transforming growth factor-b receptor 1, Smad 2 — mothers against decapentaplegic homolog 2, Smad 3 — mothers against decapentaplegic 
homolog 3, Smad 4 — mothers against decapentaplegic homolog 4, Smad 7 — mothers against decapentaplegic homolog 7, SP1 — transcription 
factor Sp1, E2F5 — transcription factor E2F5
Wnt/b-catenin pathway can be targeted by 
so-called DEmiRNAs (differentially expressed 
microRNAs) detected in interstitial lung disease 
(ILD) [143, 144]. Ting Xie et al. propose that 
miRNAs exert an influence on the Wnt/b-catenin 
signaling pathway: downregulated miR-16 and 
miR-195 influence Wnt7A, while sFRP1/2 and 
Wnt7B (Wingless-Type MMTV Integration Site Fa-
mily, Member 7B) are controlled via up-regulation 
of miR-351 [143].
However, only one original miRNA array 
study focusing on the significance of DEmiRNAs 
expression and their influence on TGF-b/Smad 
and Wnt/b-catenin signaling pathways has been 
published, which may be important in pulmonary 
sarcoidosis [122]. The authors of this study con-
firm reduced expression of miR-20a and miR-302c 
in sarcoidosis patients and elevated expression 
of miR-92b and miR-206 in lymph node tissues 
in pulmonary sarcoidosis patients [122]. Many 
types of DE-miRNAs seem also to be involved in 
regulatory signaling pathway important for sar-
coidosis [122]. These are summarized in Figure 
4 and Figure 5.
Conclusions
Sarcoidosis has confirmed to have a complex 
environmental and molecular etiopathogenesis. 
In the previous decade, sarcoidosis development 
was recognized to have a genetic basis, including 
a number of susceptibility loci which were well 
recognized from both linkage and association 
studies. These are mainly associated with human 
leukocyte antigens, both HLA class I and class 
II. Many other candidate genes have since been 
confirmed by GWAS. Based on screening of the 
genome, chromosomal regions 6p12.1, 11.q13.1, 
12q13.3 have been found to be associated with a 
significant risk of sarcoidosis. 
Recently, an experimental study examined 
non-coding RNAs (ncRNA) including miRNAs 
which play an essential role in the posttran-
scriptional regulation of numerous human genes. 
Many class of miRNAs are recognized as impor-
tant regulators of signaling pathways in lung cells. 
There is evidence that lung cells have a 
very specific miRNA expression profile, which 
undergoes modifications during lung develop-
ment. Current studies on animal models have 
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provided evidence that miRNAs participate in 
lung homeostasis and play a crucial role also in 
the control of pulmonary inflammation, TGF-b
-dependent endothelial-mesenchymal transition 
(EMT) and fibrogenesis. Recent studies confirm 
that upregulated and/or downregulated expres-
sion of various miRNAs play a pivotal role in the 
pathogenesis of sarcoidosis — via their regulatory 
impact on signaling pathways (e.g. TGF-b/Smad 
and Wnt/b-catenin). This extended knowledge of 
altered miRNA expression profiles in sarcoidosis 
may play a role in the development of new bio-
logical markers to predict disease development. 
Moreover, miRNAs may represent attractive no-
vel diagnostic biomarkers and could potentially 
provide possibilities for therapeutic intervention.
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